angiotensin-receptor blockers

systematic review meta-analysis network meta-analysis

Select acute myocardial infarctiondiabetes type 2heart failurehypertensionmiscellaneouspatients at high risk for cardiovascular events all diseases requiring ACEi (HF, CHD, HT,...)All type of patientuncoded clinical condition ***patients already receiving ACE inhibitorpatients intolerant to ACE inhibitorspatients previously untreated with ACE inhibitorspatients with preserved-LVEF heart failure       angiotensin receptor blockerangiotensin-converting enzyme inhibitorsARBs added to ACEIARBs vs ACE inhibitorsARBs vs ACEIsARBs+ACE inhibitor vs ACE inhibitorsARBs+ACEIs vs ACEIsendopeptidase inhibitors captoprilramiprilirbesartanlosartantelmisartanvalsartancandesartanolmesartan vs angiotensin receptor blockervs placebo or controlvs ACEIs vs angiotensin-converting enzyme inhibitorsvs beta-blockersvs calcium blockersvs calcium-channel blockersvs diuretics      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (175)Cardiovascular death (103)stroke (fatal and non fatal) (81)myocardial infarction (fatal and non fatal) (75)Heart failure (50)Adverse events (44)cardiovascular events (44)Hypotension (32)Diabetes onset (29)hospitalisation for heart failure (28)Coronary event (27)Hospitalization for any reason (26)Cough (25)angiodema (22)Death from any cause or hospitalization for any reason (20)Cancer (20) (18)Hyperkalaemia (13)Revascularization (9)Adverse events leading to treatment discontinuation (9)cardiac death (8)lung cancer (8)Sudden death (6)Non fatal stroke (6)Non fatal MI (6)Cardiovascular death or hospital admission for CHF (5)cancer related death (4)macrovascular events (3)cardiovascular death, MI, stroke (3)microvascular events (3)death or cardiovascular hospitalization (2)hypertension (2)Serious adverse event (2) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	Cardiovascular death
acute myocardial infarction
losartan
OPTIMAAL, 2002	Losartan	Captopril			Low risk of bias	suggesting
valsartan
VALIANT (valsartan+capropril), 2003	Valsartan+ACE inhibitor	ACE inhibitor only			Low risk of bias	negative
VALIANT (valsartan alone), 2003	Valsartan	Captopril			Low risk of bias	negative
diabetes type 2
irbesartan
IPDM (150mg), 2001	irbesartan	placebo			Low risk of bias	suggesting
IDNT (irbesartan vs amlodipine), 2001	irbesartan	amlodipine			Low risk of bias	suggesting
losartan
RENAAL, 2001	losartan	placebo			Low risk of bias	suggesting
olmesartan
ROADMAP, 2010        NCT	olmesartan	placebo			Low risk of bias	suggesting
ORIENT    NCT	olmesartan	placebo			Low risk of bias	negative
heart failure
candesartan
ARCH-J, 2003	candesartan	placebo			Low risk of bias	-
CHARM-Alternative, 2003	candesartan	placebo			Low risk of bias	suggesting
SPICE, 2000	candesartan	placebo			Low risk of bias	negative
STRETCH, 1999	candesartan	placebo			Low risk of bias	-
CHARM preserved, 2003	candesartan	placebo			Low risk of bias	-
Mitrovic et al., 2003	candesartan	placebo			Low risk of bias	suggesting
CHARM-Added, 2003	candesartan+ACE inhibitor	ACE inhibitor only			Low risk of bias	negative
RESOLVD association, 1999	candesartan+ACE inhibitor	ACE inhibitor only			Exploratory	negative
RESOLVD (candesartan alone), 1999	candesartan	enalapril			Low risk of bias	negative
irbesartan
I-PRESERVE (McMurray), 2008      NCT	ibesartan	placebo			Low risk of bias	negative
Tonkon et al., 2000	irbesartan+ACE inhibitor	ACE inhibitor only			Low risk of bias	-
losartan
HEAAL, 2009        NCT	losartan 150mg	losartan 50mg			Low risk of bias	suggesting
Losartan Phase III International, 1996	losartan	placebo			Low risk of bias	suggesting
Losartan Phase III U.S., 1995	losartan	placebo			Low risk of bias	negative
Hamroff et al., 1999	losartan+ACE inhibitor	ACE inhibitor only			Low risk of bias	-
ELITE, 1997	losartan	captopril			Low risk of bias	negative
ELITE II, 2000	losartan	captopril			Low risk of bias	-
Dickstein et al., 1995	losartan	enalapril			Low risk of bias	-
Lang et al., 1997	losartan	enalapril			Low risk of bias	-
losartan phase II US, 1996	losartan	enalapril			Low risk of bias	-
Losartan phase II S, 1996	losartan	enalapril			Low risk of bias	-
telmisartan
REPLACE, 2001	telmisartan	enalapril			Low risk of bias	-
valsartan
VALIDD, 2007    NCT	valsartan	no valsartan			Low risk of bias	negative
Mazayev et al. (vs placebo), 1998	valsartan	placebo			Low risk of bias	-
V-HeFT, 1999	valsartan+ACE inhibitor	ACE inhibitor only			Low risk of bias	negative
Val-HeFT, 2001	valsartan+ACE inhibitor	ACE inhibitor only			Low risk of bias	suggesting
HEAVEN, 2002	valsartan	enalapril			Low risk of bias	-
Mazayev et al. (vs lisinopril, 1998	valsartan	Lisinopril			Exploratory	-
hypertension
candesartan
Takahashi, 2006	candesartan	control			Exploratory	negative
HIJ-CREATE, 2009	candesartan	conventional treatment			Risk of bias	suggesting
E-COST-R, 2005	candesartan	conventional treatment			Risk of bias	negative
E-COST, 2005	candesartan	conventional treatment			Risk of bias	suggesting
SCOPE, 2003	candesartan	placebo			Low risk of bias	negative
HIJ-CREATE, 2009	Candesartan	usual care			Risk of bias	-
CASE-J, 2008	candesartan	amlodipine			Risk of bias	suggesting
ALPINE, 2003	candesartan	hydrochlorothiazide			Low risk of bias	suggesting
captopril
VALIANT/Val+Cap, 2003	Valsartan + captopril	Captopril			Low risk of bias	negative
irbesartan
IDNT (irbesartan vs pbo), 2001	irbesartan	placebo			Low risk of bias	negative
IRMA 2, 2001	irbesartan	placebo			Low risk of bias	negative
losartan
RENAAL, 2001	losartan	placebo			Low risk of bias	-
LIFE, 2002	losartan	atenolol			Low risk of bias	suggesting
ELITE, 1997	Losartan	Captopril			Low risk of bias	suggesting
ELITE-II, 2000	Losartan	Captopril			Low risk of bias	negative
OPTIMAAL, 2001	Losartan	Captopril			Risk of bias	negative
ramipril
ONTARGET/Tel+Ram, 2008	Telmisartan + ramipril	Ramipril			Low risk of bias	negative
telmisartan
PROPHESS, 2008      NCT	telmisartan	placebo			Low risk of bias	negative
DETAIL, 2004	Telmisartan	Enalapril			Low risk of bias	negative
ONTARGET/Tel, 2008	Telmisartan	Ramipril			Low risk of bias	negative
valsartan
VALIANT/Val, 2003	Valsartan	Captopril			Low risk of bias	negative
miscellaneous
candesartan
Takahashi, 2006	candesartan	control			Exploratory	negative
E-COST, 2005	candesartan	conventional treatment			Risk of bias	suggesting
E-COST-R, 2005	candesartan	conventional treatment			Risk of bias	negative
HIJ-CREATE, 2009	candesartan	conventional treatment			Risk of bias	suggesting
SCOPE, 2003	candesartan	placebo			Low risk of bias	negative
TROPHY, 2006      NCT	candesartan	placebo			Low risk of bias	suggesting
CASE-J, 2008	candesartan	amlodipine			Risk of bias	suggesting
ALPINE, 2003	candesartan	hydrochlorothiazide			Low risk of bias	suggesting
irbesartan
IDNT (irbesartan vs pbo), 2001	irbesartan	placebo			Low risk of bias	negative
IRMA 2, 2001	irbesartan	placebo			Low risk of bias	negative
losartan
RENAAL, 2001	losartan	placebo			Low risk of bias	-
LIFE, 2002	losartan	atenolol			Low risk of bias	suggesting
olmesartan
ROADMAP, 2010        NCT	olmesartan	placebo			Low risk of bias	suggesting
ORIENT    NCT	olmesartan	placebo			Low risk of bias	negative
ramipril
ONTARGET (association vs ramipril), 2008    NCT	telmisartan + ramipril	ramipril			Low risk of bias	negative
ONTARGET (association vs telmisartan), 2008    NCT	telmisartan + ramipril	telmisartan			Low risk of bias	suggesting
telmisartan
TRANSCEND, 2008    NCT	telmisartan	placebo			Low risk of bias	suggesting
PROPHESS, 2008      NCT	telmisartan	placebo			Low risk of bias	negative
ONTARGET (telmisartan alone), 2008      NCT	telmisartan	ramipril			Low risk of bias	suggesting
patients at high risk for cardiovascular events
candesartan
SCOPE, 2003	candesartan	placebo			Low risk of bias	negative
losartan
RENAAL, 2001	losartan	placebo			Low risk of bias	-
LIFE, 2002	losartan	atenolol			Low risk of bias	suggesting
ramipril
ONTARGET (association vs ramipril), 2008    NCT	telmisartan + ramipril	ramipril			Low risk of bias	negative
ONTARGET (association vs telmisartan), 2008    NCT	telmisartan + ramipril	telmisartan			Low risk of bias	suggesting
telmisartan
PROPHESS, 2008      NCT	telmisartan	placebo			Low risk of bias	negative
TRANSCEND, 2008    NCT	telmisartan	placebo			Low risk of bias	suggesting
ONTARGET (telmisartan alone), 2008      NCT	telmisartan	ramipril			Low risk of bias	suggesting